Education
About Us
Working with TipRanks
Follow Us
Capricor Therapeutics (CAPR)
NASDAQ:CAPR
Deramiocel (Cap-1002)
Muscular Dystrophy, Duchenne, Neuromuscular Diseases, Muscular Dystrophies, Nervous System Diseases, Muscular Diseases, Genetic Diseases, Inborn, Muscular Disorders, Atrophic, Genetic Diseases, X-Linked
Phase III
Active Not Recruiting
A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy
Nov 04, 2021
―
Cap-1002
COVID19
Phase II
Completed
Intravenous Infusion of CAP-1002 in Patients With COVID-19
Oct 07, 2020
―
Deramiocel (Cap-1002)
Duchenne Muscular Dystrophy
Phase II
Active Not Recruiting
Open-label Extension of the HOPE-2 Trial
Jun 09, 2020
―
Cap-1002
Muscular Dystrophy, Duchenne, Neuromuscular Diseases, Muscular Dystrophies, Nervous System Diseases, Muscular Diseases, Genetic Diseases, Inborn, Muscular Disorders, Atrophic, Genetic Diseases, X-Linked
Phase II
Completed
A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy
Jan 15, 2018
―
Allogeneic Cardiosphere-Derived Cells (Cap-1002)
Duchenne Muscular Dystrophy, Cardiomyopathy
Phase II
Completed
HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne)
Jun 19, 2015
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Capricor Therapeutics (CAPR) have in its pipeline
CAPR is currently developing the following drugs: Deramiocel (Cap-1002), Cap-1002, Deramiocel (Cap-1002). These drug candidates are in various stages of clinical development as the company works toward FDA approval.